Jazz Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Dublin Ireland (2003)

Organization Overview

First Clinical Trial
2003
NCT00003966
First Marketed Drug
2003
sodium oxybate (xyrem)
First NDA Approval
2019
solriamfetol (Sunosi)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Jazz | JAZZ | Jazz Pharamceuticals | Jazz Pharmaceuticals | Jazz Pharmaceuticals, Inc | Jazz Pharmaceuticals, Inc. | JAZZ PHARMACEUTICALS IRELAND LIMITED | JAZZ PHARMS | JAZZ PHARMS III | JAZZ PHARMS INC

Active Ingredients

Marketed Drugs (11)

Key: Jazz Pharmaceuticals (9) Acquired (2)

atoltivimab (Inmazeb) (2020)

calcium (2020)

clozapine (clozaril) (2004)

defibrotide (defitelio) (2016)

erwinia asparaginase (Erwinaze) (2011)

fluvoxamine (luvox) (2008)

lurbinectedin (Zepzelca) (2020)

maftivimab (Inmazeb) (2020)

odesivimab (Inmazeb) (2020)

sodium oxybate (xyrem) (2002)

solriamfetol (Sunosi) (2019 NDA)

Drugs in Phase 4 Trials (9)

Key: Jazz Pharmaceuticals (3) Acquired (6)

cannabidiol (Epidiolex) (7 trials)

clozapine (clozaril) (2 trials)

lidocaine (xylocaine) (1 trial)

modafinil (provigil) (2 trials)

sodium oxybate (xyrem) (22 trials)

solriamfetol (Sunosi) (13 trials)

tetracaine (pontocaine) (1 trial)

tetrahydrocannabinol (43 trials)

zolpidem (ambien) (1 trial)

Drugs in Phase 3 Trials (14)

Key: Jazz Pharmaceuticals (7) Acquired (7)

acetaminophen (tylenol) (1 trial)

atezolizumab (Tecentriq) (1 trial)

cannabis (2 trials)

carboplatin (paraplatin) (1 trial)

cytarabine (cytosar-u) (30 trials)

daunorubicin (cerubidine) (21 trials)

defibrotide (defitelio) (9 trials)

dronabinol (marinol) (3 trials)

erwinia asparaginase (Erwinaze) (8 trials)

etoposide (vepesid) (1 trial)

jzp150 (1 trial)

lurbinectedin (Zepzelca) (7 trials)

midazolam (versed) (1 trial)

siltuximab (sylvant) (3 trials)

Drugs in Phase 2 Trials (40)

Key: Jazz Pharmaceuticals (30) Acquired (10)

aldesleukin (Proleukin) (1 trial)

allogeneic cd34+ cells (1 trial)

avelumab (bavencio) (1 trial)

betaine (1 trial)

busulfan (Myleran) (1 trial)

cladribine (leustatin) (1 trial)

clonazepam (klonopin) (1 trial)

cx-8998 (3 trials)

cyclophosphamide (cytoxan) (1 trial)

dinutuximab (unituxin) (1 trial)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (2 trials)

enasidenib (idhifa) (2 trials)

Filgrastim (neupogen) (1 trial)

floxuridine (fudr) (1 trial)

fludarabine (fludara) (3 trials)

glasdegib (Daurismo) (1 trial)

hydrocortisone (solu-cortef) (1 trial)

idarubicin (idamycin) (1 trial)

irinotecan (Camptosar) (1 trial)

jzp385 (1 trial)

melphalan (alkeran) (1 trial)

mercaptopurine (purinethol) (1 trial)

methotrexate (1 trial)

midostaurin (rydapt) (2 trials)

mitoxantrone (novantrone) (1 trial)

naltrexone (revia) (1 trial)

ofatumumab (arzerra) (1 trial)

pegaspargase (oncaspar) (1 trial)

pegcrisantaspase (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (1 trial)

samarium-153 lexidronam (quadramet) (2 trials)

sodium bicarbonate (1 trial)

sodium phosphate (1 trial)

tamoxifen (nolvadex) (1 trial)

tioguanine (Lanvis) (1 trial)

urea (1 trial)

vincristine (oncovin) (1 trial)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 1 Trials (25)

Key: Jazz Pharmaceuticals (8) Acquired (17)

177lu-cyt-500 (1 trial)

bevacizumab (avastin) (1 trial)

bicalutamide (casodex) (1 trial)

chlorphenesin (maolate) (1 trial)

fluconazole (diflucan) (1 trial)

fluorothymidine (1 trial)

gemtuzumab ozogamicin (mylotarg) (2 trials)

gilteritinib (1 trial)

goserelin (zoladex) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

imgn632 (1 trial)

jzp341 (1 trial)

jzp815 (1 trial)

ketoconazole (nizoral) (1 trial)

mibefradil (Posicor) (3 trials)

moxifloxacin (avelox) (1 trial)

mpeg-r-crisantaspase (1 trial)

omeprazole (prilosec) (1 trial)

paclitaxel (taxol) (1 trial)

pentobarbital (nembutal) (1 trial)

rifampin (1 trial)

sm-153 (1 trial)

temozolomide (temodar) (1 trial)

triazolam (halcion) (1 trial)

venetoclax (venclexta) (2 trials)

Drugs in Other Trials (1)

ziconotide (prialt) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Adenocarcinoma (Phase 2)

Anemia, Refractory, with Excess of Blasts (Phase 2)

Anxiety Disorders (Phase 3)

Apnea (Phase 4)

Binge-Eating Disorder (Phase 4)

Bulimia (Phase 4)

Cataplexy (Phase 3)

Disease (Phase 3)

Disorders of Excessive Somnolence (Phase 3)

Epilepsy (Phase 2)

Essential Tremor (Phase 2)

Fatigue (Phase 4)

Fatigue Syndrome, Chronic (Phase 4)

Feeding and Eating Disorders (Phase 4)

Fibromyalgia (Phase 3)

Graft vs Host Disease (Phase 2)

Hematologic Diseases (Phase 2)

Hemiplegia (Phase 2)

Hepatic Veno-Occlusive Disease (Phase 3)

Hypersensitivity (Phase 2)

Idiopathic Hypersomnia (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Mental Disorders (Phase 4)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Myofascial Pain Syndromes (Phase 3)

Narcolepsy (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neurotoxicity Syndromes (Phase 2)

Pancreatic Neoplasms (Phase 2)

Parkinson Disease (Phase 2)

Philadelphia Chromosome (Phase 1)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 2)

REM Sleep Behavior Disorder (Phase 4)

Respiratory Aspiration (Phase 4)

Respiratory Distress Syndrome (Phase 1)

Respiratory Distress Syndrome, Newborn (Phase 1)

Schizophrenia (Phase 2)

Seizures (Phase 2)

Sleep Apnea, Obstructive (Phase 4)

Sleep Apnea Syndromes (Phase 4)

Sleepiness (Phase 3)

Sleep Initiation and Maintenance Disorders (Phase 2)

Syndrome (Phase 4)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Tremor (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 170
  • # of Trial APIs: 89